Cannabidiol Recovers Dopaminergic Neuronal Damage Induced by Reserpine or α-synuclein in Caenorhabditis elegans

Guedes, Érika da Cruz; Erustes, Adolfo Garcia; Leão, Anderson H.F.F.; Carneiro, César Alves; Abı́lio, Vanessa C.; Zuardi, Antônio Waldo; Hallak, Jaime Eduardo Cecílio; Crippa, José Alexandre S; Bincoletto, Cláudia; Smaili, Soraya Soubhi; Reckziegel, Patrícia; Pereira, Gustavo José da Silva

doi:10.1007/s11064-023-03905-z

Cited by 7 publications

(5 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, studies show that CBD ameliorates motor and cognitive impairments in animal models of PD and TD ( da Cruz Guedes et al, 2023 ; Peres et al, 2016 ). More specifically, pretreatment with CBD (0.5 mg/kg) attenuated the increase in cataleptic behavior, oral movements and memory deficits, but not locomotor activity induced by reserpine administration in rats ( Peres et al, 2016 ).…”

Section: Implications For the Potential Of Cbd As A Therapeutic Agentmentioning

confidence: 99%

“…More specifically, pretreatment with CBD (0.5 mg/kg) attenuated the increase in cataleptic behavior, oral movements and memory deficits, but not locomotor activity induced by reserpine administration in rats ( Peres et al, 2016 ). In another study where C. Elegans were exposed to reserpine, CBD exposure recovered reserpine-induced alterations in locomotion rate/food-sensing behavior, attenuated morphologic alterations and dopaminergic neuron degeneration, and reduced human α-syn protein accumulation ( da Cruz Guedes et al, 2023 ). These studies highlight the potential of CBD as a neuroprotector against PD.…”

Section: Implications For the Potential Of Cbd As A Therapeutic Agentmentioning

confidence: 99%

See 1 more Smart Citation

Cannabidiol and brain function: current knowledge and future perspectives

Schouten,

Dalle,

Mantini

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Cannabidiol (CBD) is a naturally occurring non-psychoactive cannabinoid found in Cannabis sativa, commonly known as cannabis or hemp. Although currently available CBD products do not meet the safety standards of most food safety authorities to be approved as a dietary supplement or food additive, CBD has been gaining widespread attention in recent years due to its various potential health benefits. While primarily known for its therapeutic effects in managing epileptic seizures, psychosis, anxiety, (neuropathic) pain, and inflammation, CBD’s influence on brain function has also piqued the interest of researchers and individuals seeking to enhance cognitive performance. The primary objective of this review is to gather, synthesize, and consolidate scientifically proven evidence on the impact of CBD on brain function and its therapeutic significance in treating neurological and mental disorders. First, basic background information on CBD, including its biomolecular properties and mechanisms of action is presented. Next, evidence for CBD effects in the human brain is provided followed by a discussion on the potential implications of CBD as a neurotherapeutic agent. The potential effectiveness of CBD in reducing chronic pain is considered but also in reducing the symptoms of various brain disorders such as epilepsy, Alzheimer’s, Huntington’s and Parkinson’s disease. Additionally, the implications of using CBD to manage psychiatric conditions such as psychosis, anxiety and fear, depression, and substance use disorders are explored. An overview of the beneficial effects of CBD on aspects of human behavior, such as sleep, motor control, cognition and memory, is then provided. As CBD products remain largely unregulated, it is crucial to address the ethical concerns associated with their use, including product quality, consistency, and safety. Therefore, this review discusses the need for responsible research and regulation of CBD to ensure its safety and efficacy as a therapeutic agent for brain disorders or to stimulate behavioral and cognitive abilities of healthy individuals.

show abstract

Section: Implications For the Potential Of Cbd As A Therapeutic Agentmentioning

confidence: 99%

Section: Implications For the Potential Of Cbd As A Therapeutic Agentmentioning

confidence: 99%

Cannabidiol and brain function: current knowledge and future perspectives

Schouten,

Dalle,

Mantini

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Researchers have conducted investigations into the treatment effects of CBD/THC for age-related diseases such as Alzheimer’s disease [ 173 , 174 , 175 , 176 , 177 ], dementia [ 178 , 179 ], and Parkinson’s disease [ 180 , 181 , 182 , 183 , 184 ]. However, most of these studies either focus on the PD of CBD/THC and the clinical endpoint of the disease or combine all age groups when analyzing the PK results.…”

Section: Cbd/thc Studies In Special Populationsmentioning

confidence: 99%

CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

Qian,

Beers,

Jackson

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Cannabinoid use has surged in the past decade, with a growing interest in expanding cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) applications into special populations. Consequently, the increased use of CBD and THC raises the risk of drug–drug interactions (DDIs). Nevertheless, DDIs for cannabinoids, especially in special populations, remain inadequately investigated. While some clinical trials have explored DDIs between therapeutic drugs like antiepileptic drugs and CBD/THC, more potential interactions remain to be examined. This review summarizes the published studies on CBD and THC–drug interactions, outlines the mechanisms involved, discusses the physiological considerations in pharmacokinetics (PK) and DDI studies in special populations (including pregnant and lactating women, pediatrics, older adults, patients with hepatic or renal impairments, and others), and presents modeling approaches that can describe the DDIs associated with CBD and THC in special populations. The PK of CBD and THC in special populations remain poorly characterized, with limited studies investigating DDIs involving CBD/THC in these populations. Therefore, it is critical to evaluate potential DDIs between CBD/THC and medications that are commonly used in special populations. Modeling approaches can aid in understanding these interactions.

show abstract

“…Remarkably, CBD increased dopamine concentration in the striatum independently of cannabinoid receptors CB 1 R and CB 2 R, indicating potential receptor-independent neuroprotective pathways. Moreover, a 2023 study by da Cruz Guedes et al [ 108 ] utilizing Caenorhabditis elegans models of PD found that CBD could reverse locomotor deficits induced by reserpine and α-synuclein. The study noted that CBD’s effects on behavior, such as reductions in pharyngeal pumping, did not alter other physiological functions like defecation or egg production, hinting at specific therapeutic targets.…”

Section: Research Main Overview: the Endocannabinoid System With Cann...mentioning

confidence: 99%

“…Furthermore, chickens infected with C. perfringens and treated with both CBD and Nano-Se showed fewer necrotic muscle fibers, indicating a protective effect from the combination of these bioactive substances. da Cruz Guedes et al, 2023 [ 108 ] Further research, such as the study by da Cruz Guedes et al (2023), delves into the advantages of combining CBD with other compounds for improved therapeutic outcomes. Their research indicates that supplementing CBD with nano-selenium (Nano-Se) considerably boosts vascularization, as demonstrated by the increased capillary count in chicken muscles, and decreases the incidence of muscle fiber necrosis in chickens infected with C. perfringens .…”

Section: Table A1mentioning

confidence: 99%

Cannabinoids: Potential for Modulation and Enhancement When Combined with Vitamin B12 in Case of Neurodegenerative Disorders

Kaszyńska

2024

Pharmaceuticals

View full text Add to dashboard Cite

The enduring relationship between humanity and the cannabis plant has witnessed significant transformations, particularly with the widespread legalization of medical cannabis. This has led to the recognition of diverse pharmacological formulations of medical cannabis, containing 545 identified natural compounds, including 144 phytocannabinoids like Δ9-THC and CBD. Cannabinoids exert distinct regulatory effects on physiological processes, prompting their investigation in neurodegenerative diseases. Recent research highlights their potential in modulating protein aggregation and mitochondrial dysfunction, crucial factors in conditions such as Alzheimer’s Disease, multiple sclerosis, or Parkinson’s disease. The discussion emphasizes the importance of maintaining homeodynamics in neurodegenerative disorders and explores innovative therapeutic approaches such as nanoparticles and RNA aptamers. Moreover, cannabinoids, particularly CBD, demonstrate anti-inflammatory effects through the modulation of microglial activity, offering multifaceted neuroprotection including mitigating aggregation. Additionally, the potential integration of cannabinoids with vitamin B12 presents a holistic framework for addressing neurodegeneration, considering their roles in homeodynamics and nervous system functioning including the hippocampal neurogenesis. The potential synergistic therapeutic benefits of combining CBD with vitamin B12 underscore a promising avenue for advancing treatment strategies in neurodegenerative diseases. However, further research is imperative to fully elucidate their effects and potential applications, emphasizing the dynamic nature of this field and its potential to reshape neurodegenerative disease treatment paradigms.

show abstract

Cannabidiol Recovers Dopaminergic Neuronal Damage Induced by Reserpine or α-synuclein in Caenorhabditis elegans

Cited by 7 publications

References 61 publications

Cannabidiol and brain function: current knowledge and future perspectives

Cannabidiol and brain function: current knowledge and future perspectives

CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

Cannabinoids: Potential for Modulation and Enhancement When Combined with Vitamin B12 in Case of Neurodegenerative Disorders

Contact Info

Product

Resources

About